Related Experiment Video

Updated: Apr 5, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.0K

Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?

Sara Barmettler1, Christina Price2

  • 1Department of Internal Medicine, Yale School of Medicine, New Haven, Conn.

The Journal of Allergy and Clinical Immunology
|August 17, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.7K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.6K